Molecule shows effectiveness against drug-resistant myeloma
A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline drug Velcade, researchers at Dana-Farber Cancer Institute have found.
In a study published online by the journal Cancer Cell, the investigators report that the small molecule P5091 triggered apoptosis—programmed cell death—in drug-resistant myeloma cells grown in the laboratory and in animals. The anti-myeloma effect was even more powerful when researchers combined P5091 with other therapies.
"Velcade was one of the first of a class of drugs known as proteasome inhibitors to be approved by the U.S. Food and Drug Administration for multiple myeloma treatment," says Dharminder Chauhan, PhD, lead author of the paper with Ze Tian, PhD, both of Dana-Farber. "While Velcade is successful in many patients with multiple myeloma, it often loses its effectiveness over time, which prompted us to seek other drug targets."
The proteasome acts as a cell's "garbage disposal," chewing up and disposing of unwanted proteins. Inhibiting the proteasome causes an accumulation of waste proteins that spurs cancer cell death.
The proteasome also is part of a larger mechanism known as the ubiquitin proteasome system, or UPS. The system functions by in two manners: It can attach small proteins known as ubiquitins to cell proteins, thereby ticketing those proteins for disposal by the proteasome; or it can remove ubiquitins, thus sparing the proteins from disposal.
"Dysfunction of the UPS has been linked to the development of many human diseases, including cancer, and is a valid target for therapy," Chauhan remarks.
A variety of enzymes help affix or remove ubiquitin from proteins. In the current study, investigators focused on a remover—a "deubiquitylator" known as USP7. Studies have shown that USP7 acts on many cancer-related proteins: by breaking down proteins that restrain cancer cell growth, it allows tumors to grow unabated. Patients with high levels of USP7 in their myeloma cells tend to have poorer survival rates.
In the Cancer Cell study, researchers tested whether P5091, a small molecule inhibitor of USP7 that was synthesized by Progenra, Inc., could cause the death of myeloma cell that had developed resistance to Velcade and other current therapies.
"Blocking USP7 decreases the level of a cancer-promoting protein called HDM2, which has the effect of bolstering p53 and p21, a gene that suppresses tumor cell growth," Chauhan states. "The result is that tumor cells stop growing and begin to die."
"In laboratory cell cultures, P5091 resulted in the death of myeloma cells," said the study's senior author, Kenneth Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center and the LeBow Institute for Myeloma Therapeutics at Dana-Farber. "In animal models of myeloma, this molecule impaired tumor growth, prolonged survival, and didn't harm normal tissue." When researchers combined P5091 with the drugs lenalidomide, SAHA, or dexamethasone, the myeloma-killing effects were even more pronounced.
Although P5091 itself has not been formulated into a drug, the study demonstrates "that you can target molecules in the ubiquitin proteasome system without targeting the proteasome itself and still achieve a cancer cell-killing effect, with no significant toxicity," Chauhan remarks. "Our results lay the groundwork for testing USP7 inhibitors, either alone or in combination with other drugs, in patients with multiple myeloma."
Based on the study results, Progenra plans to help lead studies of USP7 inhibitors in future clinical trials.
Journal reference: Cancer Cell
Provided by Dana-Farber Cancer Institute
- Novel drug preventing protein recycling shows potential for treating leukemia Apr 19, 2007 | not rated yet | 0
- 'Treason' by immune system cells aids growth of multiple myeloma Oct 05, 2009 | not rated yet | 0
- Novel approach scores first success against elusive cancer gene Sep 09, 2011 | not rated yet | 0
- Scientists devise new strategy to destroy multiple myeloma Aug 14, 2012 | not rated yet | 0
- Scientists unravel cancer drug's secret to resistance Mar 19, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
14 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...
Cancer 2 hours ago | not rated yet | 0
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Cancer 3 hours ago | not rated yet | 0
A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...
Cancer 4 hours ago | not rated yet | 0
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer 5 hours ago | not rated yet | 0
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer 7 hours ago | not rated yet | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
9 hours ago | 4 / 5 (4) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
3 hours ago | 5 / 5 (1) | 0
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
7 hours ago | 4.8 / 5 (6) | 0 |
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
4 hours ago | 5 / 5 (3) | 0 |
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
5 hours ago | not rated yet | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
9 hours ago | 4.8 / 5 (4) | 0 |